Erbitux and Avastin Aren’t Cost Effective, NICE Finds

 
• By The Pink Sheet Daily

Merck KGaA and Roche have 15 days to appeal the ruling regarding metastatic colorectal cancer.

More from Archive

More from Pink Sheet